1. Scrip
  2. >>Therapy Areas

Ambitious Almirall Lays Out Ebglyss Launch Plans

 
• By Kevin Grogan

The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.

Mercedes Diz
Mercedes Diz • Source: Almirall

With European Commission approval for Ebglyss secured in the middle of November, Almirall SA is ready to hit the ground running with the launch of the closely watched atopic dermatitis drug in the next fortnight in Germany.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.